13.12.2017 • News

PMC Buys Isochem’s Pharma Business

(c) SFIO CRACHO/Shutterstock
(c) SFIO CRACHO/Shutterstock

PMC Group France, a wholly owned subsidiary of US-based PMC Group International, has acquired the pharmaceuticals business of France’s Isochem for an undisclosed sum.

The business comprises research, product and process development capabilities as well as pilot-scale and full plant-scale production of drug intermediates and APIs for major companies worldwide.

Isochem operates three sites at Gennevilliers, Pithiviers and Vert-le-Petit, all within a 60-mile radius of Paris and audited by the US Food and Drug Administration (FDA) as cGMP-compliant.

Going forward, the company will be known as PMC Isochem, operating as a wholly owned subsidiary of PMC Group France.

The acquisition follows the October purchase of Indian pharma Yegna Manojavam Drugs and Chemicals by PMC Group subsidiary, PMC YM-Pharma. The Indian company’s cGMP plant is claimed to be one of the largest fluoroquinolone drug manufacturing facilities in France.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Leading Transformation
The Path to Sustainable Growth

Leading Transformation

As Executive Vice President of International Chemicals since early 2024, Antje Gerber has been steering Sasol through a pivotal reset—focused on resilience, innovation, and bold sustainability goals.

most read